Positive OS Data
Aflibercept
+ FOLFIRI (VELOUR)
3
2L
Cetuximab
+ Iri-based (EPIC)
5
2L
Panitumumab
+ FOLFIRI (Study 181)
6
2L
Bevacizumab
+ FOLFOX (E3200)
1
2L
*Not enough patients to show
statistical significance.
+ Iri-based* (ML18147)
2 **
2L
+ Oxali-based (ML18147)
2 **
2L
+ Chemo (ML18147)
2
2L
First-line regimen*:
•
Iri-based
•
Oxali-based
•
Fluoropyrimidine-
based
*ML18147 and RAISE first-line regimen included bevacizumab; VELOUR and
Study 181 included pts both with and without prior bevacizumab.
1.
Giantonio BJ, et al.
J Clin Oncol
. 2007;25:1539-1544; 2. Bennouna J, et al.
Lancet Oncol
.2013;14:29-37; 3. Van Cutsem E, et al.
J Clin Oncol
.2012;30:3499-3506; 4.
Tabernero et al. Lancet Oncol 2015; 16: 499-508, 5.
Sobrero et al.
J Clin Oncol.
2008;26:2311-2319; 6. Peeters M, et al.
J Clin Oncol
2010;28:4706–13.
Estudios pivotales 2L biológicos + QT
Ramucirumab
+ FOLFIRI (RAISE)
4
2L
